Keep current on the latest news from Allegro Ophthalmics

Sign up today to be notified about the initiation of clinical trials, study results and breaking company news.

Your info will never be shared with a third-party

No Thanks

DME retina imagery

Meeting Unmet Needs

Allegro has progressed its R&D program for its lead drug candidate, Luminate®, as a novel treatment option for DME

Luminate® has been studied in two U.S. phase 2b trials involving 218 DME patients, demonstrating safety and efficacy across doses of up to 3 mg. It achieved equivalent vision gains to the current standard of care1 – anti-VEGF treatment – with fewer total injections.2

Additionally, Luminate® has been shown to be an effective treatment option for DME patients who either do not respond or have an inadequate response to anti-VEGF therapy.2

Unlike anti-VEGF or corticosteroid therapies for DME, Luminate®2:

  • Has demonstrated antiangiogenic, anti-inflammatory, and neuroprotective activities
  • Deactivates the machinery of angiogenesis
  • Stabilizes the retina to return it to a condition of homeostasis—a normal balance

Read more about Luminate® in the news.


Reference: 1. Singer MA, Kermany DS, Waters J, et al. F1000Res. 2016;5. 2. Data on file.